Using nanoparticles to remove donor-specific antibodies from blood
Donor-specific Anti-human Leukocyte Antigen Antibodies (DSA) Re-moval From Patient Blood Using Functionalized Nanoparticles - an ex Vivo Feasibility and Proof of Principle Study
This study is testing a new way to use tiny magnetic particles to remove harmful antibodies from the blood of kidney failure patients to improve their chances of successful kidney transplants.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Zurich Academic / other |
| Locations | 1 site (Zurich, ZH) |
| Trial ID | NCT04277377 on ClinicalTrials.gov |
What this trial studies
This project focuses on developing a novel method to remove donor-specific antibodies (DSA) from the blood of patients with kidney failure using human leukocyte antigen (HLA)-coated magnetic nanoparticles. The nanoparticles are engineered to capture DSA ex vivo, allowing for their removal through magnetic separation while aiming to keep the blood components unaffected. The study will assess the efficacy and safety of this approach, particularly its interaction with other blood components to ensure no adverse inflammatory responses occur. This innovative technique represents a new strategy in managing antibody-mediated complications in kidney transplantation.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old who have detectable donor-specific antibodies in their blood.
Not a fit: Patients who are pregnant, breastfeeding, or unable to follow study procedures due to psychological or social conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this method could significantly improve outcomes for kidney transplant patients by effectively removing harmful antibodies from their blood.
How similar studies have performed: While the use of nanoparticles in medical applications is promising, this specific approach to removing donor-specific antibodies is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * DSA in the blood as detected by Luminex® * Adults (\>18 years old) * Informed written consent Exclusion Criteria: * Inability to follow the procedures of the study, due to language problems, psychological disorders, social conditions or dementia * Pregnancy and/or breast feeding * Unwillingness to participate in this study
Where this trial is running
Zurich, ZH
- University Hospital Zurich, Division of Anaesthesiology — Zurich, Zh, Switzerland (Recruiting)
Study contacts
- Principal investigator: Beatrice Beck Schimmer, Prof — University of Zurich
- Study coordinator: Beatrice Beck Schimmer, Prof
- Email: beatrice.beck@usz.ch
- Phone: +41442552696
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.